Daniel Nguyen

545 total citations
22 papers, 326 citations indexed

About

Daniel Nguyen is a scholar working on Oncology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Daniel Nguyen has authored 22 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Daniel Nguyen's work include Acute Lymphoblastic Leukemia research (5 papers), Cancer-related Molecular Pathways (5 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Daniel Nguyen is often cited by papers focused on Acute Lymphoblastic Leukemia research (5 papers), Cancer-related Molecular Pathways (5 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Daniel Nguyen collaborates with scholars based in United States, China and Norway. Daniel Nguyen's co-authors include Lan Cao, Yu Zhang, Shelya X. Zeng, Hua Lu, Wenjuan Liao, Farhad Ravandi, Nicholas J. Short, Carla Cugini, Danielle Stephens and Mary E. Davey and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Daniel Nguyen

19 papers receiving 323 citations

Peers

Countries citing papers authored by Daniel Nguyen

Since Specialization

Citations

This map shows the geographic impact of Daniel Nguyen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Nguyen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Nguyen more than expected).

Fields of papers citing papers by Daniel Nguyen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Nguyen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Nguyen. The network helps show where Daniel Nguyen may publish in the future.

Co-authorship network of co-authors of Daniel Nguyen

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Nguyen. A scholar is included among the top collaborators of Daniel Nguyen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Nguyen. Daniel Nguyen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Anti-cancer small-molecule Inauhzin-C confines its cytotoxicity to cancer cells by targeting GRP78 2025 ·Biomedicine & Pharmacotherapy ·(unknown), (unknown), Daniel Nguyen, Shelya X. Zeng, (unknown), Hua Lu	0
2	Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial 2024 ·The Lancet Haematology ·Nicholas J. Short, Daniel Nguyen, Elias Jabbour, Jayastu Senapati, Zhihong Zeng, Ghayas C. Issa, Hussein A. Abbas, (unknown), Wei Qiao, Xuelin Huang, Gautam Borthakur, Kelly S. Chien, Fadi Haddad, Naveen Pemmaraju, (unknown), (unknown), Marina Konopleva, H. Kantarjian, Farhad Ravandi	5
3	Clearance of Very Low Levels of Measurable Residual Disease with Blinatumomab Significantly Improves Outcomes in B-Cell Acute Lymphoblastic Leukemia 2024 ·Blood ·Daniel Nguyen, Elias Jabbour, Nitin Jain, (unknown), (unknown), Fadi Haddad, Jayastu Senapati, Tapan M. Kadia, Rebecca Garris, Hagop M. Kantarjian, Nicholas J. Short	2
4	Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia 2024 ·Blood ·Daniel Nguyen, Hagop Kantarjian, Nicholas J. Short, Nitin Jain, Fadi Haddad, Musa Yılmaz, Alessandra Ferrajoli, Tapan M. Kadia, (unknown), Abhishek Maiti, (unknown), Jayastu Senapati, Rebecca Garris, Min Zhao, Marina Konopleva, Farhad Ravandi, Elias Jabbour	3
5	Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors 2023 ·Blood Cancer Journal ·Nicholas J. Short, Daniel Nguyen, Farhad Ravandi	31
6	Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation 2023 ·Cancer ·Daniel Nguyen, Hagop M. Kantarjian, Nicholas J. Short, Wei Qiao, Jing Ning, Branko Cuglievan, Naval Daver, Courtney D. DiNardo, Elias Jabbour, Tapan M. Kadia, Gautam Borthakur, Guillermo Garcia‐Manero, Marina Konopleva, Michael Andreeff, Farhad Ravandi‐Kashani, Koji Sasaki, Ghayas C. Issa	9
7	Diagnostic performance of natural language processing in detection of acute cancer VTE. 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), Daniel Nguyen, Denái R. Milton, Fengyi Jin, Elliana Young, Partow Kebriaei, Cristhiam M. Rojas‐Hernandez	1
8	Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia 2023 ·Blood ·Daniel Nguyen, Hagop M. Kantarjian, Nicholas J. Short, Nitin Jain, Fadi Haddad, Musa Yılmaz, Alessandra Ferrajoli, Tapan M. Kadia, (unknown), Abhishek Maiti, (unknown), Lewis Nasr, Rebecca Garris, Marina Konopleva, Farhad Ravandi, Elias Jabbour	10
9	External validation of the HIGH‐2‐LOW model: A predictive score for venous thromboembolism after allogeneic transplant 2022 ·American Journal of Hematology ·Ang Li, Kylee L. Martens, Daniel Nguyen, Ryan Basom, Gabriela Rondón, (unknown), Elliana Young, Christopher I. Amos, Stephanie J. Lee, Christopher Davis, David García, Richard Champlin, (unknown), Partow Kebriaei, Cristhiam Rojas Hernandez	3
10	A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) 2022 ·Blood ·Daniel Nguyen, Elias Jabbour, Nicholas J. Short, Ghayas C. Issa, Musa Yılmaz, Naval Daver, Naveen Pemmaraju, Kelly S. Chien, Lucia Masárová, Farhad Ravandi, Nitin Jain, (unknown), Min Zhao, Christopher Loiselle, (unknown), (unknown), Rebecca Garris, Hagop M. Kantarjian	2
11	Nanoparticle encapsulation of non-genotoxic p53 activator Inauhzin-C for improved therapeutic efficacy 2021 ·Theranostics ·(unknown), Jieqiong Wang, Daniel Nguyen, Xiaoxiao Yang, (unknown), Jennifer L. Paruch, Li Li, Yiwei Zhang, Kun Meng, (unknown), Janarthanan Jayawickramarajah, Binghe Wang, Shelya X. Zeng, Hua Lu	2
12	Inhibition of tumor suppressor p73 by nerve growth factor receptor via chaperone-mediated autophagy 2020 ·Journal of Molecular Cell Biology ·Daniel Nguyen, Kun Yang, (unknown), Yun Deng, Xiang Zhou, Zhen Zhang, Shelya X. Zeng, Hua Lu	15
13	Reviving the guardian of the genome: Small molecule activators of p53 2017 ·Pharmacology & Therapeutics ·Daniel Nguyen, Wenjuan Liao, Shelya X. Zeng, Hua Lu	58
14	Dental plaque microbial profiles of children from Khartoum, Sudan, with congenital heart defects 2017 ·Journal of Oral Microbiology ·(unknown), Ellen Berggreen, Daniel Nguyen, Raouf Wahab Ali, Thomas E. Van Dyke, Hatice Hastürk, Manal Mustafa	10
15	Trastuzumab stimulation of ribosomal protein S6 kinase 1 (S6K1) predicts de novo trastuzumab resistance 2016 ·Biochemical and Biophysical Research Communications ·(unknown), Daniel Nguyen, Frank E. Jones	4
16	TP53 mutations in epithelial ovarian cancer 2016 ·Translational Cancer Research ·Yu Zhang, Lan Cao, Daniel Nguyen, (unknown)	94
17	Inauhzin(c) Inactivates c-Myc Independently of p53 2015 ·Cancer Biology & Therapy ·Ji Hoon Jung, Jun‐Ming Liao, Qi Zhang, Shelya X. Zeng, Daniel Nguyen, Qian Hao, Xiang Zhou, Bo Cao, Sung‐Hoon Kim, Hua Lu	13
18	Antibiotic Utilization Improvement with the Nanosphere Verigene Gram-Positive Blood Culture Assay 2015 ·Baylor University Medical Center Proceedings ·Stacy G. Beal, (unknown), Neelam Dhiman, Daniel Nguyen, Huanying Qin, (unknown), (unknown), (unknown), (unknown)	24
19	Arginine deiminase inhibits Porphyromonas gingivalis surface attachment 2012 ·Microbiology ·Carla Cugini, Danielle Stephens, Daniel Nguyen, Alpdoğan Kantarcı, Mary E. Davey	22
20	Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells. 1995 ·Molecular Pharmacology ·Jean L. Grem, F. Geoffroy, Pedro M. Politi, (unknown), D D Ross, Daniel Nguyen, S. M. Steinberg, C J Allegra	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact